prednisone has been researched along with estramustine in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 2 (5.26) | 18.2507 |
| 2000's | 29 (76.32) | 29.6817 |
| 2010's | 6 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| deKernion, JB; Lindner, A | 1 |
| Fosså, SD; Paus, E | 1 |
| Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C | 1 |
| Knox, JJ; Moore, MJ | 1 |
| Kelly, WK; Scher, HI | 1 |
| Bilkenroth, U; Froehner, M; Fuessel, S; Kraemer, K; Linné, C; Meye, A; Schmidt, U; Wirth, MP | 1 |
| Canil, CM; Tannock, IF | 1 |
| Heine, K; Wolff, JM | 1 |
| Benson, MC; Berry, D; Burch, PA; Crawford, ED; Hussain, MH; Jones, JA; Kohli, M; Lara, PN; Moinpour, C; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME | 1 |
| Areal, J; Arroyo, FR; Constenla, M; Font, A; Martin, C; Murias, A; Rosell, R; Saladie, JM; Sanchez, JJ; Santiago, JA | 1 |
| Itoh, N | 1 |
| Andrieu, JM; Banu, A; Banu, E; Beuzeboc, P; Coscas, Y; Dourthe, LM; Guinet, F; Hardy-Bessard, AC; Linassier, C; Oudard, S; Poupon, MF; Scotté, F; Voog, E | 1 |
| George, DJ; Moore, CN | 1 |
| Ferrero, JM | 1 |
| Doggrell, SA | 1 |
| Petrylak, DP | 1 |
| Kibel, AS | 1 |
| Sleijfer, S; Stoter, G | 1 |
| Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV | 1 |
| Chang, SS; Rumohr, JA | 1 |
| Kovel, S; Sella, A; Skoneczna, I; Sternberg, C; Yarom, N | 1 |
| Bladou, F; Gravis, G; Salem, N; Viens, P | 1 |
| Aitini, E; Andreuccetti, M; Antonuzzo, A; Barbieri, R; Di Marsico, R; Falcone, A; Fontana, A; Fontana, E; Galli, C; Galli, L; Landi, L | 1 |
| Burzykowski, T; Buyse, M; Collette, L | 1 |
| Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R | 1 |
| Armstrong, AJ; Eisenberger, M; Garrett-Mayer, EL | 1 |
| Bonny, MA; Clausse, M; D'Hondt, L; Dopchie, C; Duck, L; Filleul, B; Honhon, B; Jousten, P; Kerger, J; Machiels, JP; Marcelis, L; Mazzeo, F; Moxhon, AM; Tombal, B; Verhoeven, D; Verschaeve, V | 1 |
| Kovel, S; Sella, A; Skoneczna, I; Sternberg, CN | 1 |
| Donaldson, GW; Moinpour, CM; Nakamura, Y | 1 |
| Akdas, AM; Burch, PA; Crawford, ED; Dipaola, RS; Donnelly, BJ; Goldman, B; Higano, CS; Hussain, M; Petrylak, DP; Small, EJ; Sundram, SK; Tangen, C; Wilding, G | 1 |
| Dorff, TB; Quinn, DI | 1 |
| Chen, XS; Du, J; Tian, J; Yang, Q; Yao, X | 1 |
| Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X | 1 |
| Huang, C; Song, P; Wang, Y | 1 |
14 review(s) available for prednisone and estramustine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Doxorubicin; Estramustine; Fluorouracil; Humans; Imidazoles; Lomustine; Male; Methotrexate; Mitomycin; Mitomycins; Prednimustine; Prednisone; Procarbazine; Prostatic Neoplasms; Random Allocation; Streptozocin; Vincristine | 1984 |
Treatment of hormone refractory prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Male; Mitoxantrone; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Suramin | 2001 |
Is there a role for chemotherapy in prostate cancer?
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Estramustine; Estrogens; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Taxoids | 2004 |
[Chemotherapy of the hormone-refractory prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Neoplasm Staging; Palliative Care; Prednisone; Prostatic Neoplasms; Taxoids | 2004 |
[Chemotherapy for prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bridged-Ring Compounds; Docetaxel; Drug Resistance; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Update in the management of patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agonists; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epothilones; Estramustine; Humans; Male; Mitoxantrone; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
[Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Which drug combination for hormone-refractory prostate cancer?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids | 2005 |
Future directions in the treatment of androgen-independent prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Estramustine; Forecasting; Humans; Male; Mitoxantrone; Organoplatinum Compounds; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
An interdisciplinary approach to treating prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tosyl Compounds | 2005 |
Current chemotherapeutic approaches for androgen-independent prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bevacizumab; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Endothelin-1; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2006 |
[Prostate cancer and chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2007 |
The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Network Meta-Analysis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
11 trial(s) available for prednisone and estramustine
| Article | Year |
|---|---|
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Doxorubicin; Estramustine; Fluorouracil; Humans; Imidazoles; Lomustine; Male; Methotrexate; Mitomycin; Mitomycins; Prednimustine; Prednisone; Procarbazine; Prostatic Neoplasms; Random Allocation; Streptozocin; Vincristine | 1984 |
Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report.
Topics: Aged; Biomarkers, Tumor; Combined Modality Therapy; Epirubicin; Estramustine; Flutamide; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 1994 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2004 |
Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2005 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome | 2005 |
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Mitoxantrone; Prednisone; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2006 |
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Belgium; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2008 |
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Models, Statistical; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2009 |
14 other study(ies) available for prednisone and estramustine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Editorial: States and state transitions are all that really matter.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estramustine; Humans; Male; Mitoxantrone; Paclitaxel; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms | 2002 |
Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Immunomagnetic Separation; Keratins; Leukocyte Common Antigens; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Neoplastic Cells, Circulating; Paclitaxel; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Cells, Cultured | 2004 |
Doxetaxel: new indication. Prostate cancer: a few more weeks.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2006 |
Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Humans; Male; Meta-Analysis as Topic; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome | 2008 |
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2008 |
Cabazitaxel in prostate cancer: stretching a string.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Approval; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Taxoids; Tissue Extracts | 2010 |
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Taxoids; Tumor Burden | 2013 |
Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cluster Analysis; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; National Cancer Institute (U.S.); Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; United States | 2016 |